School of Pharmacy

Department of Physical Therapy

Dr. Lisa Smith

Dr. Lisa Smith

Acting Director, Dept. of Physical Therapy and Asst. Dean of Faculty

Burnside Dalton 207


University of Kentucky, PharmD
The Ohio State University, BS

About Me

I’ve been fortunate to practice pharmacy in several areas including community, hospital, long-term care, geriatrics and nutrition support before entering academia in 2004. My current areas of interest include GI/liver diseases and faculty development.

Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ. Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2014.

Love BL, Johnson A, Smith LS. Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome. AJHP 2014; 71:1081-1091.

Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Annals of Pharmacotherapy. 2013; 47:1348-52.

Klibanov OM, Vickery SB, Olin JB, Smith LS, Williams SH. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Pharmacotherapy 2012; 32:173-90.

Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB. Telaprevir: A novel NS3/4 Protease Inhibitor for the treatment of Hepatitis C. Pharmacotherapy 2011; 31:951-74.

Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A Protease Inhibitor for the treatment of chronic hepatitis C. Annals of Pharmacotherapy 2011; 45:639-48.

Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-alpha antagonist for the treatment of moderate-to-severe Crohn’s disease. Annals of Pharmacotherapy 2010; 44:333-42.

Smith LS, Greene J, Meade L, et al. Qualitative analysis of students’ attitudes of duration of community pharmacy practice experiences. Currents in Pharmacy Teaching and Learning 2009; 1(2): 110-14.

Haase KK, Resman-Targoff BH, Herner SJ, Smith L. ACCP White Paper: Quality Experiential Education. Pharmacotherapy 2008; 28(10):219e–227e).

Haase KK, Resman-Targoff BH, Herner SJ, Smith L. ACCP Position Statement: Ensuring Quality Experiential Education. Pharmacotherapy 2008; 28(12):1548–1551).

Update on Irritable Bowel Syndrome. 2015 ACCP Annual Meeting, San Francisco, CA.

Special Session: “Curricular Integration—Meeting 2016 ACPE Standards.” 2015 AACP Annual Meeting, Washington, DC.

“Curriculum Committee Strategies on Addressing the CAPE Outcomes.” 2015, Live Webinar for AACP.

Key Issue Debate: “Tenure is Outdated.” AACP 2015 Interim Meeting Presentation of the ALFP 2014/2015 Cohort, Austin, TX.

“Lower sustained virologic response rates in a hepatology clinic vs phase III clinical trials for the NS3/4A inhibitors boceprevir and telaprevir.” ACCP 2014 Virtual Symposium.

Update on the Management of IBD. ACCP 2010 Annual Meeting, Austin, TX.

“Development and Implementation of Basic Clinical Skills in Inpatient and Ambulatory Care.” AACP 2006 Annual Meeting, San Diego, CA.